[{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"acc6da2f-38b7-4ab4-ba2e-48ab70259f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532552","created_at":"2025-02-26T13:41:40.179Z","updated_at":"2025-02-26T13:41:40.179Z","phase":"Phase 2","brief_title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06532552","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 07/29/2024","start_date":" 07/29/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-11-20"},{"id":"23a26ba2-c7b3-4108-b7df-8c971e5ceef9","acronym":"DEL Biomarker","url":"https://clinicaltrials.gov/study/NCT06652152","created_at":"2025-02-26T12:22:45.189Z","updated_at":"2025-02-26T12:22:45.189Z","phase":"","brief_title":"Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma","source_id_and_acronym":"NCT06652152 - DEL Biomarker","lead_sponsor":"Ruijin Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-22"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"01bb6da0-1295-4869-97f4-aac2478019c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674683","created_at":"2021-01-19T20:45:32.528Z","updated_at":"2025-02-25T14:29:47.853Z","phase":"Phase 3","brief_title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","source_id_and_acronym":"NCT04674683","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • PD-L1 negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-06-24"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"0fe10839-16f3-4ebf-97c8-7feb7f85fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083208","created_at":"2021-10-19T15:58:00.734Z","updated_at":"2024-07-02T16:35:05.553Z","phase":"Phase 1/2","brief_title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT05083208","lead_sponsor":"Henan Cancer Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/20/2022","start_date":" 02/20/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-07"},{"id":"48501323-09cb-4f5b-a243-32ead55180fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05370547","created_at":"2022-05-11T15:55:57.619Z","updated_at":"2024-07-02T16:35:16.239Z","phase":"Phase 1/2","brief_title":"Chidamide Bridging for CAR-T Therapy","source_id_and_acronym":"NCT05370547","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • BCL6 • PMAIP1","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • PMAIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"b256a039-fd2a-468d-ac7b-e44e1e11c391","acronym":"KEPIDA-2","url":"https://clinicaltrials.gov/study/NCT05833724","created_at":"2023-04-27T14:05:13.981Z","updated_at":"2024-07-02T16:35:17.751Z","phase":"Phase 2","brief_title":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","source_id_and_acronym":"NCT05833724 - KEPIDA-2","lead_sponsor":"Great Novel Therapeutics Biotech \u0026 Medicals Corporation","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-26"},{"id":"dac5d115-7904-464c-a96a-a31864a53af9","acronym":"ABC","url":"https://clinicaltrials.gov/study/NCT06220487","created_at":"2024-01-24T16:19:51.060Z","updated_at":"2024-07-02T16:35:22.410Z","phase":"Phase 2","brief_title":"A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL","source_id_and_acronym":"NCT06220487 - ABC","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • prednisone • Epidaza (chidamide) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-24"},{"id":"7d670f75-2f18-4cb3-9f44-0fc426b7febe","acronym":"CINDERELLA","url":"https://clinicaltrials.gov/study/NCT05464173","created_at":"2022-07-19T14:54:26.715Z","updated_at":"2024-07-02T16:35:22.701Z","phase":"Phase 1/2","brief_title":"Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib","source_id_and_acronym":"NCT05464173 - CINDERELLA","lead_sponsor":"Biyun Wang, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-01-22"},{"id":"0fab3fc5-371c-4513-860f-4d767f471226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05281276","created_at":"2022-03-16T16:55:17.375Z","updated_at":"2024-07-02T16:35:26.269Z","phase":"Phase 1","brief_title":"Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)","source_id_and_acronym":"NCT05281276","lead_sponsor":"Taipei Medical University Shuang Ho Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-14"},{"id":"1e82c7a9-fdab-4a93-b27d-b001dd636e57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02718066","created_at":"2021-01-18T13:17:44.848Z","updated_at":"2024-07-02T16:35:29.778Z","phase":"Phase 1b/2","brief_title":"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02718066","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-11-09"},{"id":"8ea8c998-c65d-43e9-9569-c90fcbef5c48","acronym":"","url":"https://clinicaltrials.gov/study/NCT05566054","created_at":"2022-10-04T13:56:45.538Z","updated_at":"2024-07-02T16:35:29.819Z","phase":"Phase 2","brief_title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","source_id_and_acronym":"NCT05566054","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-11-09"},{"id":"c6d4f78d-e9fb-44fb-b084-86b60a1d4509","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087419","created_at":"2023-10-17T15:12:56.219Z","updated_at":"2024-07-02T16:35:30.632Z","phase":"Phase 1/2","brief_title":"A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients","source_id_and_acronym":"NCT06087419","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-11-02"},{"id":"59b4180b-7e59-4251-bca1-bb5607428e51","acronym":"NeoTEE","url":"https://clinicaltrials.gov/study/NCT04465097","created_at":"2021-01-18T21:27:43.316Z","updated_at":"2024-07-02T16:35:33.358Z","phase":"Phase 2","brief_title":"Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer","source_id_and_acronym":"NCT04465097 - NeoTEE","lead_sponsor":"First Affiliated Hospital, Sun Yat-Sen University","biomarkers":" ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • exemestane • goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-10-17"},{"id":"fa2dfd4a-182a-4a19-8b7a-6b4d4ecaddfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04022005","created_at":"2021-01-17T17:36:16.942Z","updated_at":"2024-07-02T16:35:37.525Z","phase":"Phase 2","brief_title":"Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL","source_id_and_acronym":"NCT04022005","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Epidaza (chidamide)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 06/19/2019","start_date":" 06/19/2019","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 03/11/2023","study_completion_date":" 03/11/2023","last_update_posted":"2023-09-11"},{"id":"7a85cb36-6636-4b7a-af50-42acb1ec66e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231448","created_at":"2021-01-18T20:35:06.017Z","updated_at":"2024-07-02T16:35:38.070Z","phase":"Phase 3","brief_title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","source_id_and_acronym":"NCT04231448","lead_sponsor":"Chipscreen Biosciences, Ltd.","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 07/05/2023","primary_completion_date":" 07/05/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-06"},{"id":"d08d0e16-df57-4b5e-a8b7-7669765049cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983107","created_at":"2023-08-09T14:09:24.430Z","updated_at":"2024-07-02T16:35:40.474Z","phase":"Phase 2","brief_title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT05983107","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • Epidaza (chidamide) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 07/15/2026","primary_completion_date":" 07/15/2026","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2023-08-09"},{"id":"c13bf7f2-7d71-4a67-ac7d-1ce03f5aeb55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05931263","created_at":"2023-07-05T14:08:35.001Z","updated_at":"2024-07-02T16:35:43.965Z","phase":"Phase 3","brief_title":"A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL","source_id_and_acronym":"NCT05931263","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Epidaza (chidamide) • carmustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-07-04"},{"id":"fe45ab61-61ea-4d16-b7bb-2d511d2834aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04735068","created_at":"2021-02-02T15:52:25.047Z","updated_at":"2024-07-02T16:35:44.366Z","phase":"Phase 2","brief_title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04735068","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 04/09/2021","start_date":" 04/09/2021","primary_txt":" Primary completion: 08/21/2022","primary_completion_date":" 08/21/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-06-29"},{"id":"53537bf3-eae7-42ad-947c-fe82b3ec3eae","acronym":"ERRITI","url":"https://clinicaltrials.gov/study/NCT04619316","created_at":"2021-01-19T20:34:09.715Z","updated_at":"2024-07-02T16:35:45.180Z","phase":"Phase 2","brief_title":"Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition","source_id_and_acronym":"NCT04619316 - ERRITI","lead_sponsor":"University Hospital, Essen","biomarkers":" TG","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-06-22"},{"id":"08d7c682-d778-4669-b253-ec0728656c1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890287","created_at":"2023-06-06T14:06:55.812Z","updated_at":"2024-07-02T16:35:46.393Z","phase":"","brief_title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","source_id_and_acronym":"NCT05890287","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • Epidaza (chidamide) • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-06-06"}]